Form 4: CFO Sells Avidity Biosciences Shares for Tax Obligations

Avidity Biosciences' CFO, Michael F. MacLean, sold 4,542 shares of common stock at $72.45 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc., reported a sale of common stock.
• The transaction involved the disposition of 1,807 shares and 2,735 shares of Avidity Biosciences common stock.
• The shares were sold at a price of $72.45 per share on January 21, 2026.
• The total number of shares sold was 4,542.
• Following these transactions, MacLean beneficially owns 59,290 shares of common stock directly.
• The sales were non-discretionary "sell-to-cover" transactions, mandated by the company's equity incentive plans to satisfy tax withholding obligations from RSU vesting on January 20, 2026.
• The transactions were executed pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes, which does not indicate a change in management's sentiment or company performance.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued employment and compensation for the Chief Financial Officer.
• The sale was a non-discretionary transaction for tax purposes, not reflecting a change in management's confidence in the company's future.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Management Comments

• This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person.
• The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Industry Context

This transaction is a routine insider filing (Form 4) detailing a 'sell-to-cover' event, which is common across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive dynamics.

Related Party Transactions

• The transaction involves the Chief Financial Officer, a related party, selling company stock to cover tax obligations arising from equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale that does not signal a lack of confidence from management.
• Employees: The vesting of RSUs is a positive for the CFO, indicating continued compensation as part of their employment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary "sell-to-cover" transaction by the CFO to satisfy tax obligations arising from RSU vesting. Such transactions are common for executives receiving equity compensation and do not typically reflect a change in the insider's view of the company's prospects or fundamental performance. Therefore, this specific filing provides no new information that would warrant a change in investment recommendation; a "hold" stance is maintained, pending further operational or financial updates.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Trading, Michael F. MacLean, CFO, Stock Sale, Tax Withholding, RSU Vesting, Rule 10b5-1